We serve Chemical Name:Cobalt tetrakis(pentafluorophenyl)porphyrin CAS:52242-06-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:Cobalt tetrakis(pentafluorophenyl)porphyrin
CAS.NO:52242-06-5
Synonyms:Cobalt tetrakis(pentafluorophenyl)porphyrin
Molecular Formula:C44H8CoF20N4
Molecular Weight:N/A
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:
Exact Mass:
LogP:
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like Cobalt tetrakis(pentafluorophenyl)porphyrin chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Cobalt tetrakis(pentafluorophenyl)porphyrin physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Cobalt tetrakis(pentafluorophenyl)porphyrin Use and application,Cobalt tetrakis(pentafluorophenyl)porphyrin technical grade,usp/ep/jp grade.
Related News: Novavax, a Maryland biotechnology company that has struggled mightily with delays in developing its coronavirus vaccine, announced Monday that its two-shot regimen was over 90% effective overall in a trial that unfolded even as more contagious variants emerged. Cobalt tetrakis(pentafluorophenyl)porphyrin manufacturer With the global industrial division of labor and the change in the business model of multinational pharmaceutical companies, the outsourced market for patented drug substances will further expand. Cobalt tetrakis(pentafluorophenyl)porphyrin supplier In addition to APIs, a variety of pharmaceutical excipients are contained in the medicine. Cobalt tetrakis(pentafluorophenyl)porphyrin vendor In addition to APIs, a variety of pharmaceutical excipients are contained in the medicine. Cobalt tetrakis(pentafluorophenyl)porphyrin factory Novavax, a Maryland biotechnology company that has struggled mightily with delays in developing its coronavirus vaccine, announced Monday that its two-shot regimen was over 90% effective overall in a trial that unfolded even as more contagious variants emerged.
